scholarly journals Multicenter Clinical Trials Analyzing Efficacy and Safety of Topical Cortex Phellodendri Compound Fluid in Treatment of Diabetic Foot Ulcers

2020 ◽  
Vol 26 ◽  
Author(s):  
Yali Liu ◽  
Youshan Li ◽  
Yuqing Du ◽  
Tianyi Huang ◽  
Chunyan Zhu
2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Kathrin H. Beckmann ◽  
Gesa Meyer-Hamme ◽  
Sven Schröder

Diabetic foot ulcers as one of the most common complications of diabetes mellitus are defined as nonhealing or long-lasting chronic skin ulcers in diabetic patients. Multidisciplinary care for the diabetic foot is common, but treatment results are often unsatisfactory. Low level laser therapy (LLLT) on wound areas as well as on acupuncture points, as a noninvasive, pain-free method with minor side effects, has been considered as a possible treatment option for the diabetic foot syndrome. A systematic literature review identified 1764 articles on this topic. Finally, we adopted 22 eligible references; 8 of them were cell studies, 6 were animal studies, and 8 were clinical trials. Cell studies and animal studies gave evidence of cellular migration, viability, and proliferation of fibroblast cells, quicker reepithelization and reformed connective tissue, enhancement of microcirculation, and anti-inflammatory effects by inhibition of prostaglandine, interleukin, and cytokine as well as direct antibacterial effects by induction of reactive oxygen species (ROS). The transferral of these data into clinical medicine is under debate. The majority of clinical studies show a potential benefit of LLLT in wound healing of diabetic ulcers. But there are a lot of aspects in these studies limiting final evidence about the actual output of this kind of treatment method. In summary, all studies give enough evidence to continue research on laser therapy for diabetic ulcers, but clinical trials using human models do not provide sufficient evidence to establish the usefulness of LLLT as an effective tool in wound care regimes at present. Further well designed research trials are required to determine the true value of LLLT in routine wound care.


2015 ◽  
Vol 46 (6) ◽  
pp. 470-478 ◽  
Author(s):  
Luis Cañedo-Dorantes ◽  
Luis R. Soenksen ◽  
Clara García-Sánchez ◽  
Daphny Trejo-Núñez ◽  
Fernando Pérez-Chávez ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-12 ◽  
Author(s):  
Wentao Huang ◽  
Yongsong Chen ◽  
Nasui Wang ◽  
Guoshu Yin ◽  
Chiju Wei ◽  
...  

Background. Acellular matrix (AM) therapy has shown promise in the treatment of diabetic foot ulcers (DFUs) in several studies. The clinical effects of AM therapy were not well established. Therefore, we conducted a meta-analysis of randomized clinical trials (RCTs) to examine the efficacy and safety of AM therapy for patients with DFUs. Methods. A literature search of 5 databases was performed to identify RCTs comparing AM therapy to standard therapy (ST) in patients with DFUs. The primary outcome was the complete healing rate and the secondary outcomes mainly included time to complete healing and adverse events. Results. Nine RCTs involving 897 patients were included. Compared with ST group, patients allocated to AM group had a higher complete healing rate both at 12 weeks (risk ratio RR=1.73, 95% confidence interval (CI): 1.31 to 2.30) and 16 weeks (RR=1.56, 95% CI: 1.28 to 1.91), a shorter time to complete healing (mean difference MD=−2.41; 95% CI: -3.49 to -1.32), and fewer adverse events (RR=0.64, 95% CI: 0.44 to 0.93). Conclusion. The present study suggests that AM therapy as an adjuvant treatment could further promote the healing of full-thickness, noninfected, and nonischemia DFUs. AM therapy also has a safety profile. More large well-designed randomized clinical trials with long follow-up duration are needed to further explore the efficacy and safety of AM therapy for DFUs.


2005 ◽  
Vol 6 (1) ◽  
pp. 27-40 ◽  
Author(s):  
Lawrence Harkless ◽  
Jack Boghossian ◽  
Richard Pollak ◽  
Wayne Caputo ◽  
Adrian Dana ◽  
...  

Author(s):  
Wee Teck Lim ◽  
Helen Robinson ◽  
Edward Jude ◽  
Satyan Rajbhandari

The total contact cast (TCC) is considered the gold standard treatment to off-load diabetic foot ulcers (DFUs); however, the use of TCC can be limited due to various reasons such as underlying infections, ischemia, and patient’s reluctance. Removable cast walkers are used in such cases, and the VACOped boot is one such device. The aim of this study was to analyze the results of the VACOped boot in the treatment of DFUs in real life. Case records of all patients with DFUs treated with a VACOped from 2011 to 2017 were reviewed retrospectively. Eighty-three episodes of ulcerations in 42 subjects were identified, of which 48 (57.8%) healed in a median duration of 17.5 (95% confidence interval = 15-33) weeks with the use of the VACOped and 35 (42.2%) discontinued its use. The median duration of healing with the VACOped of 17.5 weeks appears to be longer, but this cohort included patients with underlying infection and ischemia, which are often excluded in the clinical trials of off-loading. Our data show that the VACOped application is preferred by many patients and seems to be equally effective to other removable cast walkers.


2014 ◽  
Vol 11 (5) ◽  
pp. 554-560 ◽  
Author(s):  
Lawrence A Lavery ◽  
James Fulmer ◽  
Karry Ann Shebetka ◽  
Matthew Regulski ◽  
Dean Vayser ◽  
...  

2009 ◽  
Vol 6 (2) ◽  
pp. 159-166 ◽  
Author(s):  
Hoa Le Tuyet ◽  
Tram Tran Nguyen Quynh ◽  
Hien Vo Hoang Minh ◽  
Dao Nguyen Thi Bich ◽  
Thang Do Dinh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document